Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.73 USD
Change Today +0.13 / 3.61%
Volume 23.9K
OCRX On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (OCRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - $8.19
52 Week Low
04/30/15 - $3.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ocera therapeutics inc (OCRX) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (OCRX) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.

16 Employees
Last Reported Date: 03/13/15

ocera therapeutics inc (OCRX) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $425.0K
Chief Business Officer
Total Annual Compensation: $213.5K
Chief Development Officer
Total Annual Compensation: $152.1K
Compensation as of Fiscal Year 2014.

ocera therapeutics inc (OCRX) Key Developments

Ocera Therapeutics, Inc. Announces Resignation of Rajiv Patni as the Chief Development Officer Effective as of June 1, 2015

On April 30, 2015, Rajiv Patni, tendered his resignation as the Chief Development Officer of Ocera Therapeutics, Inc. effective as of June 1, 2015. Dr. Patni's resignation was not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

Ocera Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Year 2015

Ocera Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $31,000 against $45,000 a year ago. Loss from operations was $6,664,000 against $5,195,000 a year ago. Net loss from continuing operations was $6,651,000 or $0.34 per basic and diluted share against $5,182,000 or $0.34 per basic and diluted share a year ago. Net loss was $6,651,000 or $0.34 per basic and diluted share against $4,065,000 or $0.27 per basic and diluted share a year ago. For the year 2015, the company reiterates its previous guidance and expects net use of cash for 2015 to be between $28.0 million and $32.0 million. Ocera expects that it will have sufficient cash to fund operations into the fourth quarter of 2016 based on its current operating plan.

Jean-Paul Castaigne and Lars G. Ekman Not to Stand for Re-Election to Ocera Therapeutics Board of Directors

On April 23, 2015, each of Jean-Paul Castaigne, M.D. and Lars G. Ekman, M.D., Ph.D. informed the Board of Directors of Ocera Therapeutics, Inc. of their intention not to stand for re-election at the Company's 2015 Annual Meeting of Shareholders, and to retire from the Board effective as of the date of the Annual Meeting. Dr. Castaigne currently serves as a member of the Audit Committee and the Compensation Committee of the Board. The decisions by Dr. Castaigne and Dr. Ekman not to stand for reelection were not a result of any disagreement with the Company or the Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCRX:US $3.73 USD +0.13

OCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation OCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 217.4x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 83.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at